Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: Mura confers clinical resistance at low fitness cost by Cauce, Alejandro et al.
Genomewide Overexpression Screen for Fosfomycin Resistance in
Escherichia coli: MurA Confers Clinical Resistance at Low Fitness Cost
Alejandro Couce,a Alejandra Briales,b Alexandro Rodríguez-Rojas,a Coloma Costas,a Álvaro Pascual,b and Jesús Blázqueza
Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain,a and Departamento de Microbiología, Universidad de Sevilla, Seville,
Spainb
To determine whether the overexpression of chromosomal genes can confer fosfomycin resistance, genomewide screening of a
complete set of 5,272 plasmid-expressed open reading frames of Escherichia coli (ASKA collection) was performed. Major results
are that (i) no clinical level of resistance is achieved by overexpressing chromosomal genes, except murA; (ii) this level is reached
at a low fitness cost; and (iii) this cost is much lower than that imposed by other mutations conferring fosfomycin resistance.
The emergence of antibiotic resistance mutants in a bacterialpopulation is shaped by several factors, and both the mutation
rate and the fitness cost of resistance are particularly relevant (2).
If resistance came at a high fitness cost, the growth rate would not
be enough to offset the clearance imposed by the host or to prevent
the bacteria from being outcompeted by fitter susceptible bacteria
once the antibiotic is removed (2).
Fosfomycin (Fos) is a broad-spectrum bactericidal antibiotic
active against both Gram-positive and Gram-negative bacteria
(7). Conveniently, Fos treatments have shown a relatively low
likelihood that resistant mutants will persist in vivo, probably due
to the high biological cost of resistance mutations, leading to good
therapeutic effectiveness (19).
Fos resistance is acquired mainly by reducing the cell’s drug
uptake (4, 10, 11, 22), although active efflux, target alterations,
and plasmid-encoded resistance have also been described in Esch-
erichia coli and other species (18, 21, 23, 24). Resistant mutations
usually entail a moderate to high fitness cost (1, 15, 19), as well as
reduced virulence (8, 13, 15), which has been invoked to explain
the low prevalence of resistant strains (19). Despite this, a signifi-
cant increase in resistance has been recently described after anti-
biotic pressure in the community (20), suggesting that there may
be other, unidentified, ways to attain less costly high-level Fos
resistance.
The genome of E. coli harbors a substantial reservoir of resis-
tance genes whose overexpression can decrease susceptibility (22).
The complete E. coli open reading frame (ORF) ASKA library has
already been screened for resistance to 237 toxins and antibiotics.
However, Fos was not included among the drugs used to screen
for resistance. Given the renewed interest in Fos treatment, we
explored the capacity of the overexpression of chromosomal E.
coli genes to confer clinical levels of Fos resistance by screening the
complete ASKA library (12).
Genomewide overexpression screening for Fos resistance.
The complete ASKA library was replicated in duplicate in 96-well
plates containing Luria-Bertani (LB) broth plus chloramphenicol
(50 g/ml) with and without isopropyl--D-thiogalactopyrano-
side (IPTG) to a final concentration of 100 M and incubated
overnight at 37°C. The transcription of the cloned genes of the
ASKA collection is under the control of the Ptac promoter, which
is induced by the addition of IPTG (12). A 5-l sample from each
well was spotted onto an LB agar plate containing either 32 g/ml
Fos (the EUCAST breakpoint for Enterobacteriaceae [http://www
.eucast.org/clinical_breakpoints/]) or no antibiotic. Plates were
incubated for 24 h at 37°C. Only 1 of the 5,272 clones was able to
grow on Fos. The clone, containing plasmid pCA24N-murA, was
isolated from the original frozen 96-well plate and introduced by
transformation into strain MG1655. Three independent transfor-
mants were isolated, and Fos resistance was verified as indicated
above. The presence of the wild-type murA gene in the plasmid
was verified by sequencing. Therefore, under our experimental
conditions, no clinical level of Fos resistance can be achieved by
the overexpression of chromosomal genes, except murA.
Effect of murA overexpression on Fos resistance level. MICs
of Fos for strains MG1655(pCA24N) and MG1655(pCA24N-
murA) were determined by the broth microdilution method as
recommended by the CLSI (3), except that LB broth was used
instead of Mueller-Hinton medium. Table 1 shows how increases
in murA transcription, caused by rising IPTG concentrations, pro-
mote strong increases in the MIC of Fos.
Effect of murA overexpression on growth rate. To gain a
quantitative insight into the fitness cost imposed by this type of
resistance, growth curves in the presence of different concentra-
tions of IPTG (3.3, 10, 33, and 100 M) were recorded. Overnight
cultures were diluted 1:100, and growth was resumed for 4 h, with
and without different concentrations of IPTG. Cultures of the
control and murA-carrying strains were then diluted 1:36 in LB
broth plus IPTG in a final volume of 180 l per well in a flat-
bottom 96-well plate. The plate was covered with a lid to prevent
evaporation and incubated at 37°C in a multiwell fluorimeter.
Optical density at 595 nm was recorded every 10 min after 10 s of
orbital shaking. Two controls were included, strain MG1655 har-
boring the vector pCA24N and the strain expressing murA,
MG1655(pCA24N-murA), without IPTG. Figure 1A shows that
the addition of IPTG, even at the higher concentration, did not
produce any effect on the growth of the control strain in LB broth.
On the contrary, when the expression of murA was increased by
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the addition of different concentrations of IPTG, the growth of
MG1655(pCA24N-murA) was affected (Fig. 1B).
These results indicated that overproduction of MurA confers a
fitness cost proportional to the level of transcription (Fig. 2),
which opens the possibility for evolutionary adjustment of the
resistance-fitness tradeoff. In particular, clinical resistance levels
(32 g/ml) can be achieved at a low fitness cost (about 5%, the
result of interpolation in Fig. 2), whereas the fitness cost of the
commonly found permeability mutants (with altered GlpT and/or
UhpT functionality) has been estimated to be 20% (19). A sim-
ple calculation can illustrate the meaning of this fitness costs, in
terms of how long it will take for a wild-type strain to dominate the
population. Assuming that both wild-type and mutant popula-
tions grow exponentially and excluding de novo mutations, it can
be easily shown that the time needed to vary the ratio of mutant to
wild-type bacteria by factor C (tC) is equal to logWC, where w is the
relative fitness of the mutant (ratio of the growth rates). Calculat-
ing tC with fitness costs of 5% and 20%, respectively, shows that it
will take murA overexpression mutants more than four times as
long as permeability mutants to be outcompeted by the wild type
in the absence of antibiotic pressure. The exact number of gener-
ations depends on C. For example, it will take the wild-type 51.6
generations to increase its frequency from 0.001% to 90% against
permeability mutants, whereas it will take 224.5 generations
against overexpression mutants.
Due to the current scarcity of new antibiotics, Fos has been
proposed as an alternative treatment for infections caused by a
wide variety of bacteria (7). Our genomewide screening has shown
that of the 5,272 chromosomal genes tested, only 1, murA, is able
to confer clinical levels of resistance when overexpressed. Even
TABLE 1 Effect of murA transcription level on fosfomycin MIC for
strain MG1655 containing either pCA24N (vector alone) or pCA24N-
murA (expressing murA)
IPTG concn (M)







FIG 1 Growth curves at different IPTG concentrations. The values shown are averages of seven independent experiments. Different shades of gray represent
different concentrations of IPTG. (A) Growth of control strain MG1655 carrying the cloning vector pCA24N. (B) Growth of the strain carrying murA-expressing
plasmid pCA24N-murA.
FIG 2 Tradeoff between fitness and resistance. Fitness and MICs were esti-
mated for strain MG1655 with a plasmid harboring the murA gene at different
levels of induction (expressed as concentrations of IPTG). The growth rate was
estimated as the maximum slope of the natural logarithm of optical densities
versus time. Curve fitting was done using a regression spline method (4, 24),
and fitness was calculated as the ratio of the growth rate at each concentration
of IPTG to that without IPTG (16). These measurements were determined
from seven independent cultures, and a single mean relative fitness level was
calculated for each condition. Error bars represent standard deviations.
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though the effect of overexpression of murA on Fos resistance has
been described already (9, 16, 19), our results indicate that no
other chromosomal genes can produce Fos resistance by overex-
pression. In addition, we show that overproduction of MurA to a
level high enough to produce clinical Fos resistance exacts a fitness
cost significantly lower than that imposed by other mutations
found in clinical isolates (19).
How likely are mutant bacteria overexpressing murA to be se-
lected in vivo? Apart from the fitness cost, the mutation rate also
plays a major role in determining this probability (2). Overexpres-
sion mutants could easily arise under natural conditions by in-
creasing RNA polymerase binding affinity through promoter mu-
tation, by disrupting gene control expression as described for
other resistance determinants (6, 17), or by acquiring foreign
DNA segments via, for instance, insertion sequences with strong
promoter activity (5, 14). In any case, further clinical studies are
necessary to determine the relative importance of this mechanism
of resistance.
ACKNOWLEDGMENTS
This work was supported by grants PI10/00105 and REIPI RD06/0008
from the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III
(the latter was cofinanced by the European Development Regional Fund
“A Way to Achieve Europe” ERDF); by the Spanish Network for Research
on Infectious Diseases (REIPI RD06/0008); and by the PAR project
(241476) from the EU 7th Framework Programme.
REFERENCES
1. Alós JI, Garcia-Pena P, Tamayo J. 2007. Biological cost associated with
fosfomycin resistance in Escherichia coli isolates from urinary tract infec-
tions. Rev. Esp. Quimioter. 20:211–215.
2. Andersson DI, Levin BR. 1999. The biological cost of antibiotic resis-
tance. Curr. Opin. Microbiol. 2:489 – 493.
3. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for
bacteria that grow aerobically. Approved standard—7th edition. CLSI
M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Cordaro JC, et al. 1976. Fosfomycin resistance: selection method for
internal and extended deletions of the phosphoenolpyruvate:sugar phos-
photransferase genes of Salmonella typhimurium. J. Bacteriol. 128:785–
793.
5. Corvec S, et al. 2003. AmpC cephalosporinase hyperproduction in Acin-
etobacter baumannii clinical strains. J. Antimicrob. Chemother. 52:629 –
635.
6. Depardieu F, Courvalin P, Kolb A. 2005. Binding sites of VanRB and
sigma70 RNA polymerase in the vanB vancomycin resistance operon of
Enterococcus faecium BM4524. Mol. Microbiol. 57:550 –564.
7. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. 2008.
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
Clin. Infect. Dis. 46:1069 –1077.
8. Gismondo MR, et al. 1994. Escherichia coli: effect of fosfomycin trometa-
mol on some urovirulence factors. J. Chemother. 6:167–172.
9. Horii T, Kimura T, Sato K, Shibayama K, Ohta M. 1999. Emergence of
fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia
coli O26. Antimicrob. Agents Chemother. 43:789 –793.
10. Kadner RJ, Winkler HH. 1973. Isolation and characterization of muta-
tions affecting the transport of hexose phosphates in Escherichia coli. J.
Bacteriol. 113:895–900.
11. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. 1974. The mechanism of
action of fosfomycin (phosphonomycin). Ann. N. Y. Acad. Sci. 235:364 –
386.
12. Kitagawa M, et al. 2005. Complete set of ORF clones of Escherichia coli
ASKA library (a complete set of E. coli K-12 ORF archive): unique re-
sources for biological research. DNA Res. 12:291–299.
13. Klein U, Pawelzik M, Opferkuch W. 1985. Influence of beta-lactam
antibiotics, fosfomycin and vancomycin on the adherence (hemagglutina-
tion) of Escherichia coli-containing different adhesins. Chemotherapy 31:
138 –145.
14. Maki H, Murakami K. 1997. Formation of potent hybrid promoters of
the mutant llm gene by IS256 transposition in methicillin-resistant Staph-
ylococcus aureus. J. Bacteriol. 179:6944 – 6948.
15. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. 2003. In vitro
activity of fosfomycin against gram-negative urinary pathogens and the
biological cost of fosfomycin resistance. Int. J. Antimicrob. Agents
22(Suppl. 2):53–59.
16. Marquardt JL, Siegele DA, Kolter R, Walsh CT. 1992. Cloning and
sequencing of Escherichia coli murZ and purification of its product, a
UDP-N-acetylglucosamine enolpyruvyl transferase. J. Bacteriol. 174:
5748 –5752.
17. McAleese FM, Foster TJ. 2003. Analysis of mutations in the Staphylococ-
cus aureus clfB promoter leading to increased expression. Microbiology
149:99 –109.
18. Mendoza C, et al. 1980. Plasmid-determined resistance to fosfomycin in
Serratia marcescens. Antimicrob. Agents Chemother. 18:215–219.
19. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003.
Biological costs and mechanisms of fosfomycin resistance in Escherichia
coli. Antimicrob. Agents Chemother. 47:2850 –2858.
20. Oteo J, et al. 2010. Parallel increase in community use of fosfomycin and
resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-
producing Escherichia coli. J. Antimicrob. Chemother. 65:2459 –2463.
21. Poole K. 2005. Efflux-mediated antimicrobial resistance. J. Antimicrob.
Chemother. 56:20 –51.
22. Soo VW, Hanson-Manful P, Patrick WM. 2011. Artificial gene amplifi-
cation reveals an abundance of promiscuous resistance determinants in
Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 108:1484 –1489.
23. Takahata S, et al. 2010. Molecular mechanisms of fosfomycin resistance
in clinical isolates of Escherichia coli. Int. J. Antimicrob. Agents 35:333–
337.
24. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. 2010. Preva-
lence of fosfomycin resistance among CTX-M-producing Escherichia coli
clinical isolates in Japan and identification of novel plasmid-mediated
fosfomycin-modifying enzymes. Antimicrob. Agents Chemother. 54:
3061–3064.
Fosfomycin Resistance at Low Fitness Cost
May 2012 Volume 56 Number 5 aac.asm.org 2769
 on July 26, 2017 by U
S
E
/B
C
T
A
.G
E
N
 U
N
IV
E
R
S
IT
A
R
IA
http://aac.asm
.org/
D
ow
nloaded from
 
